New frontline regimens in advanced stage: a head-on collision or the possibility of diversification based on patient type?
P. Borchmann
New frontline regimens in advanced stage: a head-on collision or the possibility of diversification based on patient type?
C.H. Moskowitz
Has the dream of having effective CAR-Ts faded?
C.A. Ramos
SESSION II - PTCL/CTCL

Chairman: S.P. Iyer

The vision of a diversified first-line therapy in PTCL
K.J. Savage
New targeted agents in PTCL: could the light at the end of the tunnel be near?
S.P. Iyer
Will we have the opportunity to rapidly develop therapeutic modalities (sequential/combined) that could raise the bar in terms of OS, PFS and potential cure in CTCL?
J. Zain
SESSION III - DLBCL (excluded CAR-T)

Chairman: S.M. Ansell

Capturing and targeting the molecular heterogeneity in DLBCL
D.W. Scott
The front lines of the near future (one, one hundred, one thousand): can we consider differentiated choices based on “different” patients?
S.M. Ansell
The new concept in R/R patient is the combination of Mab’s and ADC’s: current picture and future developments (moving from right to left?)
J.R. Westin
Overview of the treatment algorithm for R/R patients ineligible for CAR-T and ABMT: current picture and potential new drugs
S.M. Ansell
Bispecific, trispecific and tetra...
M. Hutchings
SESSION IV - Follicular lymphoma

Chairman: C.R. Flowers

The transition from second line to first line “chemo-free” regimens: will it be a winning concept in terms of healing potential? Will the “maintenance” regimen disappear/be permanently reduced?
L. Falchi
DEBATE one year later: any news? Pro CAR-T
J.S. Abramson
DEBATE one year later: any news? Pro bispecifics
M. Hutchings
The therapeutic world of follicular lymphoma is changing rapidly: could it be reasonable to evaluate an update of some parameters such as POD24, W&W, FLIPIs score and Deauville score?
L. Falchi
SESSION V - Lectures

Chairman: P.L. Zinzani

BTK degraders: update of the results and their role in combination
A.V. Danilov
Therapeutic news from the world of Waldenström macroglobulinemia
S.P. Treon
High-grade B-cell lymphoma: the impact of new therapeutic approaches (CAR-T, bispecifcs, Mab plus ADC)
J.S. Abramson
SESSION VI - CAR-T cells

Chairman: S.J. Schuster

CAR-T for follicular lymphoma: next generation
S.S. Neelapu
CAR-T for DLBCL: next generation
S.J. Schuster
Multi-targeted and in vivo CARs
J.S. Abramson
5 years from now: what will be the role of CAR-T in the therapeutic strategy of the “lymphoma world”?
S.S. Neelapu
SESSION VII - Mantle cell lymphoma

Chairman: M. Dreyling

In light of the frontline use of the TRIANGLE and ECHO studies, can an algorithm be defined for the different types of patients with particular attention to some ‘gray’ areas?
M. Dreyling
CAR-T for MCL: next generation
M. Wang
The bispecifics in monotherapy and in combination
T.J. Phillips
Privacy Policy | Cookie Policy